Completed PHASE2 INTERVENTIONAL NCT00055367

Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease

A Phase II, International, Multicenter, Open Label Study of the Safety, Tolerability and Effectiveness of Three Intravenous Infusions of Antegren (Natalizumab) in Adolescents With Moderately to Severely Active Crohn's Disease

Sponsor: Biogen

Conditions Crohn's Disease

Interventions natalizumab

Updated 6 times since 2017 Last updated: Jun 14, 2016 Started: Apr 30, 2002 Primary completion: May 31, 2004 Completion: May 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00055367, this PHASE2 trial focuses on Crohn's Disease and remains completed. Sponsored by Biogen, it has been updated 6 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biogen
Elan Pharmaceuticals

Data source: Biogen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Boston, United States , Charlotte, United States , Edinburgh, United Kingdom , Hartford, United States , Hershey, United States , London, United Kingdom , Los Angeles, United States , Miami, United States , Milwaukee, United States and 2 more locations